首页> 外文期刊>Nuclear Medicine Review >The effects of radioisotope therapy and radiotherapy in subjects with breast cancer with bone metastases
【24h】

The effects of radioisotope therapy and radiotherapy in subjects with breast cancer with bone metastases

机译:放射性同位素治疗和放射治疗对患有骨转移的乳腺癌患者的影响

获取原文
           

摘要

BACKGROUND: Metastatic bone disease is found in 80-90% of patients examined after death and is a serious problem in everyday practice. The aim of the study was the evaluation of the survival time of patients with bone metastases in relation to the prognostic group and applied treatment. MATERIAL AND METHODS: The authors analyzed 84 patients treated in the Radiotherapy Division of Lower Silesian Oncology Centre during the years 1997-2004. Radioisotope treatment was conducted in the Department of Nuclear Medicine of the 4 th Military Clinical Hospital in Wroc?aw. The average age of the patients was 53.1 years. The women differed in staging at the moment of diagnosis. The patients were divided into two groups with different clinical prognoses. In addition to systemic treatment (biphosphonates, chemotherapy or hormonotherapy), 32 (38.1%) patients were treated with teletherapy and 20 (23.8%) underwent radioisotope therapy. In 32 (38.1%) patients both methods were applied. The analysis of results included the estimation of overall survival (OS) meaning the time of survival from the onset of disease to one of the end points. End points of the observation were defined by the authors as the patient’s death or last control visit. The Kaplan-Meier method was used. RESULTS: The outcomes of the observation are closely connected with particular prognostic groups. The Kaplan-Meier’s diagrams presented here indicate that teletherapy combined with radioisotope therapy was the most beneficial for the patients with metastases in bones and other organs. CONCLUSIONS: The best effects of the treatment measured by overall survival were obtained with combined treatment: radiotherapy and radioisotopes, in the group with bone and extra- skeletal metastases.
机译:背景:在死后接受检查的患者中,有80-90%发现了转移性骨病,这在日常实践中是一个严重的问题。该研究的目的是评估骨转移患者的生存时间与预后组和应用治疗的关系。材料与方法:作者分析了下西里西亚肿瘤中心放疗科在1997年至2004年期间治疗的84例患者。放射性同位素的治疗是在弗罗茨瓦夫第4军事临床医院的核医学科进行的。患者的平均年龄为53.1岁。妇女在诊断时的分期有所不同。将患者分为两组,临床预后不同。除全身治疗(双膦酸盐,化学疗法或激素疗法)外,还有32(38.1%)例患者接受了远程治疗,其中20例(23.8%)接受了放射性同位素治疗。在32名(38.1%)患者中,两种方法均被应用。结果分析包括总体生存期(OS)的估计,即从疾病发作到终点之一的生存时间。作者将观察终点定义为患者的死亡或最后一次对照访视。使用Kaplan-Meier方法。结果:观察结果与特定的预后组密切相关。此处显示的Kaplan-Meier图表明,远距治疗与放射性同位素治疗相结合对骨头和其他器官转移的患者最有益。结论:在骨和骨骼外转移组中,放疗和放射性同位素联合治疗获得了以总生存期衡量的最佳治疗效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号